1ILMN Stock Chart & Stats
€196.52
-€0.98(-0.57%)
At close: 4:00 PM EDT
€196.52
-€0.98(-0.57%)
Day’s Range― - ―
52-Week Range€49.00 - €257.00
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
€28.04B
Enterprise Value€28.37K
Total Cash (Recent Filing)€1.17B
Total Debt (Recent Filing)€2.53B
Price to Earnings (P/E)39.5
Beta0.43
Next Earnings
Oct 29, 2026EPS Estimate
1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding151,000,000
10 Day Avg. Volume43
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€168.25Price Target Upside-14.39% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)4.62
Revenue Forecast (FY)€3.99B
Bulls Say, Bears Say
Bulls Say
Installed-base And Consumables ModelNovaSeq X placements expand the installed base that generates recurring reagent and flow-cell demand. Rising clinical utilization and conversion to the platform can support consumables pull-through and revenue visibility beyond initial instrument sales.
Improving Revenue OutlookHigher guidance following strong quarterly growth indicates improving execution and customer adoption across sequencing markets. The outlook also points to a broader recovery, with clinical demand helping offset weakness in research consumables.
Strong Margins And Cash GenerationHigh gross and operating margins, together with substantial operating and free cash flow, provide resources for product development, debt service and capital returns. This financial capacity supports investment while the business scales.
Bears Say
Persistent Research Consumables WeaknessResearch customers remain cautious amid funding uncertainty, creating a structural drag on utilization and consumables revenue. Continued weakness could delay recovery in a major customer segment and limit the pace of overall growth.
Leverage And Refinancing ExposureModerate-to-elevated leverage reduces flexibility if earnings weaken or investment needs rise. Although refinancing extends part of the maturity profile, debt obligations and interest costs remain constraints on resilience through a softer operating cycle.
Earnings Durability Remains UnevenThe rebound demonstrates recovery potential but also highlights sensitivity to demand, costs and operating conditions. Prior losses and negative trailing EPS growth make the improved profitability less proven and increase execution risk over the next several quarters.
Illumina News
1ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was €49.00 and its highest was €257.00 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is €28.04B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Oct 29, 2026 which is in 58 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Jul 30, 2026. The company reported €1.135 earnings per share for the quarter, beating the consensus estimate of €1.063 by €0.073.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.18.
How many shares outstanding does Illumina have?
Illumina has 151,000,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of €1.135 in its last earnings report, beating expectations of €1.063. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in IT:1ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€168.25 (-14.39% Downside)
€168.25 (-14.39% Downside)
Blogger Sentiment
Bullish
IT:1ILMN Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $487.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
1ILMN Company Deck
1ILMN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: Illumina delivered a quarter with strong top-line beats, materially higher instrument placements (especially NovaSeq X), margin outperformance, raised full-year guidance and strengthened multi-omics and BioInsight momentum (Billion Cell Atlas revenue and partners). Headwinds remain—memory and freight costs, inventory/tax timing impacts, and continued weakness in research consumables and some regions—but management has absorbed costs, secured supply, and raised guidance while reaffirming long-term targets. The positive operational and financial beats and the upgraded outlook outweigh the listed challenges.View all IT:1ILMN earnings summaries1ILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
1ILMN Stock 12 Month Forecast
Average Price Target
€168.25
▼(-14.39% Downside)